POLBF News and Press, Poolbeg Pharma plc Ord GBP 0.0002

2024-07-26 03:36:49 ET More on Poolbeg Pharma Historical earnings data for Poolbeg Pharma Financial information for Poolbeg Pharma Read the full article on Seeking Alpha For further details see: Poolbeg Pharma to voluntarily delist from OTCQB market

LONDON, UK / ACCESSWIRE / July 26, 2024 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF) 'Poolbeg' or the 'Company'), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces that it is voluntaril...

LONDON, UNITED KINGDOM / ACCESSWIRE / July 10, 2024 / TR-1: Standard form for notification of major holdings This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the U...

Change of Registered Address LONDON, UK / ACCESSWIRE / July 2, 2024 / Poolbeg Pharma  (AIM:POLB)(OTCQB:POLBF), ('Poolbeg' or the 'Company'), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medi...

Results of Annual General Meeting LONDON, UNITED KINGDOM / ACCESSWIRE / June 17, 2024 /   Poolbeg Pharma  (AIM:POLB)(OTCQB:POLBF) ‘Poolbeg' or the ‘Company'), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines ta...

(NewsDirect) Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) chief legal officer John McEvoy joins Proactive's Stephen Gunnion with news that POLB 001's Immuno-modulator II has received the fully granted patent from the US Patent Office. McEvoy explained the patent encompasses a class of d...

(NewsDirect) Poolbeg Pharma PLC CEO Jeremy Skillington and Tim Coté CEO of Silk Road Therapeutics join Proactive's Stephen Gunnion with details of an exclusive 12-month option agreement with Silk Road Therapeutics for Poolbeg to acquire a novel topical drug aimed at treating oral ulc...

Significant POLB 001 Patent Granted in United States Immunomodulator II patent grant further strengthens robust intellectual property portfolio for partnering LONDON, UK / ACCESSWIRE / May 1, 2024 / Poolbeg Pharma  (AIM:POLB)(OTCQB:POLBF, 'Poolbeg' or the 'Company'), a biopharm...

2024-04-30 10:30:52 ET More on Poolbeg Pharma Poolbeg Pharma announces board role change and launch of EIP Historical earnings data for Poolbeg Pharma Financial information for Poolbeg Pharma Read the full article on Seeking Alpha For further details ...

Significant pipeline advancements Strategic expansion into cancer immunotherapy-induced CRS unlocking a market opportunity exceeding US$10Bn Key senior management hires LONDON, UK / ACCESSWIRE / April 30, 2024 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF); 'Poolbeg' or the 'Company')...